a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10632552			
Filing Date		2003-08-02			
First Named Inventor	Marco	os Karnezos			
Art Unit		2815			
Examiner Name	Chris	C. Chu			
Attorney Docket Number		CPAC 1017-5			

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No Patent Number		Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	6441496		2002-08-27	Chen et al.	
	2	6650019		2003-11-18	Glenn et al.	
	3	6847105		2005-01-25	Koopmans	
	4	6930396		2005-08-16	Kurita et al	
	5	6593662		2003-07-15	Pu et al.	
	6	5652185		1997-07-29	Lee	
	7	6445064		2002-09-03	Ishii et al.	
	8	6690089		2004-02-10	Uchida	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10632552	
Filing Date		2003-08-02	
First Named Inventor	Marcos Karnezos		
Art Unit		2815	
Examiner Name	Chris	C. Chu	
Attorney Docket Number		CPAC 1017-5	

			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹			Name of Patentee or Applicant		Pages,Columns,Lines when Relevant Passages or Relev Figures Appear			
	1	20020096755		2002-07	2002-07-25 Fukui et al.						
	2	20040212096		2004-10	1-28	Wang					
	3	20060043556		2006-03	1-02	Su et al.					
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d buttor	n. Add		
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	ner Cite Foreign Document Country No Number 3 Country Code 2 i Code Date Document No Number Relé Passages Code Document		evant or Relevant	т.							
	1										
If you wisl	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner initials* Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc.), date, pages(s), volume-issue numbor(s), publisher, city and/or country where published.									Ţŝ		
	1										_
If you wis	h to a	dd additional non-paten	t literatu	re docu	ment cit	ation informat	ion please click the	Add b	utton Ad	id	L

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10632552		
Filing Date		2003-08-02		
First Named Inventor	Marc	os Karnezos		
Art Unit		2815		
Examiner Name Chris		C. Chu		
Attorney Docket Number		CPAC 1017-5		

	EXAMINER SIGNATURE							
Examiner Signature		Date Considered						
*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through a								

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10632552	
	Filing Date		2003-08-02	
First Named Inventor Marco		Marco	os Karnezos	
	Art Unit		2815	
Examiner Name Chris		Chris	C. Chu	
	Attorney Docket Number		CPAC 1017-5	

CERTIFICATION STATEMENT

Please see	37	CFR	1.97	and	1 98 h	n make the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Bill Kennedy

_ ...

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

33407

Toma or the dignature.			
Signature	/BILL KENNEDY/	Date (YYYY-MM-DD)	2006-12-29

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.